261 related articles for article (PubMed ID: 31603099)
21. A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression.
Keske A; Shetty S; Weisman P; Yu Q; McGregor SM; Xu J
Pathol Res Pract; 2023 Aug; 248():154628. PubMed ID: 37399589
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer.
Narita D; Raica M; Suciu C; Cîmpean A; Anghel A
Folia Histochem Cytobiol; 2006; 44(3):165-72. PubMed ID: 16977795
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement.
Sofi GN; Sofi JN; Nadeem R; Shiekh RY; Khan FA; Sofi AA; Bhat HA; Bhat RA
Asian Pac J Cancer Prev; 2012; 13(10):5047-52. PubMed ID: 23244108
[TBL] [Abstract][Full Text] [Related]
24. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
25. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
26. Factors Associated With Node-Positive Disease in Estrogen Receptor-Positive Breast Cancer Patients.
Gallagher J; Elleson KM; Englander K; Chintapally N; Sun W; Whiting J; Laronga C; Lee MC
J Surg Res; 2024 Mar; 295():327-331. PubMed ID: 38061237
[TBL] [Abstract][Full Text] [Related]
27. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
[TBL] [Abstract][Full Text] [Related]
28. Expression and clinical significance of androgen receptor in triple negative breast cancer.
Luo X; Shi YX; Li ZM; Jiang WQ
Chin J Cancer; 2010 Jun; 29(6):585-90. PubMed ID: 20507730
[TBL] [Abstract][Full Text] [Related]
29. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
30. Positive immunohistochemical expression of bcl-2 in hormone-independent breast carcinomas is associated with a greater lymph node involvement and poor outcome.
Ruibal Á; Aguiar P; Del Río MC; Menéndez P; Arias JI; Herranz M
Med Oncol; 2014 Aug; 31(8):105. PubMed ID: 25008065
[TBL] [Abstract][Full Text] [Related]
31. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers.
Ogawa Y; Hai E; Matsumoto K; Ikeda K; Tokunaga S; Nagahara H; Sakurai K; Inoue T; Nishiguchi Y
Int J Clin Oncol; 2008 Oct; 13(5):431-5. PubMed ID: 18946753
[TBL] [Abstract][Full Text] [Related]
34. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors.
Selim AG; El-Ayat G; Wells CA
J Clin Pathol; 2002 Jan; 55(1):14-6. PubMed ID: 11825917
[TBL] [Abstract][Full Text] [Related]
36. Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status.
Zhang X; Eliassen AH; Tamimi RM; Hazra A; Beck AH; Brown M; Collins LC; Rosner B; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):962-8. PubMed ID: 25855627
[TBL] [Abstract][Full Text] [Related]
37. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters.
Kuenen-Boumeester V; Van der Kwast TH; Claassen CC; Look MP; Liem GS; Klijn JG; Henzen-Logmans SC
Eur J Cancer; 1996 Aug; 32A(9):1560-5. PubMed ID: 8911118
[TBL] [Abstract][Full Text] [Related]
38. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
[TBL] [Abstract][Full Text] [Related]
39. NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.
Asch-Kendrick RJ; Samols MA; Lilo MT; Subhawong AP; Sharma R; Illei PB; Argani P; Cimino-Mathews A
J Clin Pathol; 2014 Sep; 67(9):768-71. PubMed ID: 24996432
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
